论文部分内容阅读
1例59岁女性患者,因高脂血症口服血滞通胶囊2粒/次,3次/d。用药前血清总胆固醇8.43 mmol/L,三酰甘油3.86 mmol/L,低密度脂蛋白胆固醇5.28 mmol/L;丙氨酸转氨酶37 U/L,天冬氨酸转氨酶33 U/L,γ-谷氨酰转移酶(γ-GT)46 U/L,总胆红素10.9μmol/L。服用血滞通胶囊4周后血脂各项指标均有所改善,但γ-GT升高至166 U/L,遂停用血滞通胶囊。停药2个月后γ-GT下降至86 U/L,3个月后降至59 U/L。患者自行再次服用血滞通胶囊4周后停药,肝功能检测示γ-GT159 U/L,2个月后γ-GT降至92 U/L。
A case of 59-year-old female patients, due to hyperlipidemia blood capsule 2 capsules / times, 3 times / d. Before treatment, serum total cholesterol 8.43 mmol / L, triglyceride 3.86 mmol / L, low density lipoprotein cholesterol 5.28 mmol / L; alanine aminotransferase 37 U / L, aspartate aminotransferase 33 U / L, 46 U / L of amino-acyltransferase (γ-GT) and 10.9 μmol / L of total bilirubin. After taking blood lead capsule for 4 weeks, the indexes of blood lipids improved, but γ-GT increased to 166 U / L, then stop using blood lead capsule. Γ-GT decreased to 86 U / L after 2 months of withdrawal and dropped to 59 U / L after 3 months. Patients taking the blood through the capsule after 4 weeks of withdrawal, liver function tests showed γ-GT159 U / L, 2 months after the γ-GT dropped to 92 U / L.